IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346

Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269

BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells

O’Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C. L., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,130

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Terpos, E., Kleber, M., Engelhardt, M. M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 995

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744

Tutorial in biostatistics: the self‐controlled case series method

Whitaker, H. J., Paddy Farrington, C., Spiessens, B., & Musonda, P. (2006) · Statistics in Medicine · doi:10.1002/sim.2302 · Cited by 719

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 667

Current understanding and management of CAR T cell-associated toxicities

Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 352

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 119

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Mohan, M., Monge, J., Shah, N. N., Luan, D., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01003-z · Cited by 106

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Frerichs, K. A., Verkleij, C. P. M., Mateos, M., Martin, T. G., Rodriguez, C., Nooka, A. K., Banerjee, A., Chastain, K. M., Perales‐Puchalt, A., Stephenson, T., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011658 · Cited by 105

Bispecific antibodies in the treatment of multiple myeloma

Devasia, A. J., Chari, A., & Lancman, G. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01139-y · Cited by 94

Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review

Géraud, A., Hueso, T., Laparra, A., Bigé, N., Ouali, K., Cauquil, C. A., Stoclin, A., Danlos, F., Hollebecque, A., Ribrag, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114075 · Cited by 91

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma

Costa, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 89

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study

Jourdes, A., Cellerin, E., Touzeau, C., Harel, S., Denis, B., Escure, G., Faure, E., Jamard, S., Danion, F., Sonntag, C., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.02.023 · Cited by 77

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B., Nishimura, N., Farzana, T., Rueda, C., Chung, D., Landau, H., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01043-5 · Cited by 31

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Sim, B. Z., Longhitano, A., Er, J., Harrison, S. J., Slavin, M. A., & Teh, B. W. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00808-8 · Cited by 50

Bispecific antibodies: unleashing a new era in oncology treatment

Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 51

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies

Bangolo, A., Amoozgar, B., Mansour, C., Zhang, L., Gill, S. K., Ip, A., & Cho, C. (2025) · Cancers · doi:10.3390/cancers17020282 · Cited by 50

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma

Mohan, M., Szabó, A., Cheruvalath, H., Clennon, A., Bhatlapenumarthi, V., Patwari, A., Balev, M., Bhutani, D., Shrestha, A., Thanendrarajan, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01282-0 · Cited by 47

Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels

Banerjee, R. K., Mohan, M., Rejeski, K., Puliafito, B. R., Cirstea, D. D., Kaur, G., Midha, S., McCaughan, G. J. B., Kumar, N. M., Mehra, N., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016490 · Cited by 40

An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma

Firestone, R., Lesokhin, A. M., & Usmani, S. Z. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0176 · Cited by 33

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma

Stock, S., Bücklein, V., Blumenberg, V., Magno, G., Emhardt, A., Holzem, A. M. E., dos Santos, D. M. C., Schmidt, C., Grießhammer, S., Frölich, L., et al. (2025) · HemaSphere · doi:10.1002/hem3.70062 · Cited by 29

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma

Pan, D., & Richter, J. R. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00740-z · Cited by 30

Advances in the critical care management for patients with hematological malignancies

Azoulay, É., Zafrani, L., Nates, J. L., Maillard, A., Chean, D., Ferreyro, B. L., Nelson, J. E., Bauer, P. R., Puxty, K. A., Gutiérrez, C., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101306 · Cited by 26

IgG replacement in multiple myeloma

Wonnaparhown, A., Hilal, T., Squire, J., Freeman, C., & Fonseca, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01107-6 · Cited by 23

T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment

van de Donk, N. W. C. J., Rasche, L., Sidana, S., Zweegman, S., & Garfall, A. L. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0124 · Cited by 26

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium

Razzo, B. M., Midha, S., Portuguese, A. J., Grajales-Cruz, A. F., Corraes, A. D. M. S., Costello, P., Liu, Y., Sperling, A. S., Nadeem, O., Dima, D., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0354 · Cited by 25

BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them

Rees, M. J., & Kumar, S. K. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2284088 · Cited by 22

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives

Waldschmidt, J. M., Rasche, L., Kortüm, K. M., & Einsele, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.11.012 · Cited by 23

Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Tix, T., Alhomoud, M., Shouval, R., Iacoboni, G., Cliff, E. R. S., Hansen, D. K., Usmani, S. Z., Salles, G. A., Perales, M., dos Santos, D. M. C., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.048 · Cited by 22

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies

Bröckelmann, P. J., Cliff, E. R. S., Iacoboni, G., Simon, F., Horowitz, M. M., Keating, A., Mateos, M., Mohty, M., Sidana, S., Song, Y., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00051-1 · Cited by 20

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs

Jelinek, T., Žihala, D., Zabaleta, A., Kostopoulos, I. V., Souček, O., Venglár, O., Moreno, C., Fotiou, D., Radova, E., Tamariz‐Amador, L., et al. (2025) · Blood · doi:10.1182/blood.2025029572 · Cited by 20

Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

Parrondo, R. D., Ailawadhi, S., & Cerchione, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394048 · Cited by 21

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review

Sassine, J., Siegrist, E. A., & Chemaly, R. F. (2025) · Viruses · doi:10.3390/v17010133 · Cited by 19

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma

Golmohammadi, M., Raza, S., Albayyadhi, M., Sholehrasa, H., Khouri, J., Williams, L., Hansen, D. K., Moradi, A., Xu, X., Albliwi, M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01334-5 · Cited by 18

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection

Yee, A. J. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01091-x · Cited by 17

Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies

Techaapornkun, P., Rojpalakorn, W., Mejun, N., Khaniya, A., Thammahong, A., Thu, M. S., Hirankarn, N., & Pitakkitnukun, P. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06524-6 · Cited by 14

Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient

Arvanitis, P., Farmakiotis, D., & Pelcovits, A. (2024) · Current Oncology · doi:10.3390/curroncol31050202 · Cited by 13

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

Shrivastava, T., van Rhee, F., & Hadidi, S. A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s370880 · Cited by 13

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1

Cai, Z., Xia, Z., He, A., Dong, Y., Wang, Y., Liao, A., Song, Y., Song, J., Uhlar, C., Chastain, K. M., et al. (2024) · Cancer · doi:10.1002/cncr.35665 · Cited by 12

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma

Dima, D., Banerjee, R., & Hansen, D. K. (2025) · Hematology · doi:10.1182/hematology.2025000721 · Cited by 12

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

Mo, C. C., Richardson, E., Calabretta, E., Corrado, F., Kocoglu, M. H., Baron, R. M., Connors, J. M., Iacobelli, M., Wei, L. J., Rapoport, A. P., et al. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101218 · Cited by 10

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

Morè, S., Corvatta, L., Manieri, V. M., Morsia, E., & Offidani, M. (2024) · Cancers · doi:10.3390/cancers16122263 · Cited by 9

Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma

O’Donnell, E., Gift, T., Yousif, Z. K., Khandelwal, N., Desai, R., Huynh, L. Y., Clear, L., Pinaire, M., Ye, M., Banatwala, A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015477 · Cited by 9

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis

Štork, M., Radocha, J., Mihályová, J., Špıčka, I., Pika, T., Jungová, A., Boichuk, I., Mensikova, K., Štraub, J., Sedlák, F., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06529-1 · Cited by 9

Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab

Smits, F., Groen, K., Korst, C. L. B. M., Frerichs, K. A., Kuipers, I., Kruyswijk, S., de Ruijter, M. E. M., Nasserinejad, K., Zweegman, S., & van de Donk, N. W. C. J. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01451-9 · Cited by 9

Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach

Kannan, A., Jeffrey, K., Misbah, S., & Ramasamy, K. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101287 · Cited by 11

Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians

Lupia, T., Cani, L., Bringhen, S., Rosa, F. G. D., Bruno, B., Mikulska, M., Corcione, S., & Mina, R. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.05.002 · Cited by 8

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis

Li, W., Zhao, D., Yu, J., Dong, W., Wang, Z., & Yan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565407 · Cited by 8

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis

Hoffmann, M., Jeker, B., Huynh‐Do, U., Banz, Y., Godau, J., Weber, E., Bacher, U., & Pabst, T. (2025) · Hematological Oncology · doi:10.1002/hon.70120 · Cited by 8

Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies

Zhou, X., Waldschmidt, J. M., & Einsele, H. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101342 · Cited by 9

T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS

Mancuso, K., Talarico, M., Manzato, E., Barbato, S., Tacchetti, P., Zamagni, E., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17091514 · Cited by 9

Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies

Piron, B., Rodrigo, L., Tessoulin, B., Gastinne, T., Dubruille, V., Letailleur, V., Antier, C., Lok, A., Leroy, E., Moreau, P., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.024 · Cited by 7

Infections after bispecific antibodies in B-cell lymphomas

Kim, D. H., Lee, N., Koh, Y., Jo, H. J., Kang, C. K., Choe, P. G., Park, W. B., Lee, C. M., Byun, J. M., & Kim, N. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017366 · Cited by 7

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

Portuguese, A. J., Davis, J. A., Raza, S., Puglianini, O. A. C., Freeman, C., Alsina, M., Wright, C., Blue, B. J., Baz, R. C., Shain, K. H., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01477-z · Cited by 10

The impact of institutional measures on optimal use of intravenous immunoglobulin

Champagne, J., Desîlets, A., Roy, G., Landon‐Cardinal, O., Chapdelaine, H., Matte, G., Bouchard, C., Rioux‐Massé, B., & Lemay, A. (2024) · Transfusion · doi:10.1111/trf.18031 · Cited by 7

Are we there yet? CAR ‐T therapy in multiple myeloma

Mirvis, E., & Benjamin, R. (2024) · British Journal of Haematology · doi:10.1111/bjh.19896 · Cited by 8

Supportive care in myeloma—when treating the clone alone is not enough

Zweegman, S., & van de Donk, N. W. C. J. (2024) · Hematology · doi:10.1182/hematology.2024000579 · Cited by 7

Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study

Derman, B. A., Roach, M., Lin, D., Wu, B., Murphy, R., Kim, N., Doyle, M., Prood, N., Fowler, J., Marshall, A., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2352856 · Cited by 6

Mechanistic Insights and Advances of Bispecific T Cell Engaging Antibodies Therapy in Multiple Myeloma

Tang, T. F., Cheong, C. S., Looi, C. Y., Wong, W. F., & Gan, G. G. (2025) · Medicina · doi:10.3390/medicina61122113 · Cited by 7

Defining infection risk of bispecific antibodies for myeloma

Hammond, S. P. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013813 · Cited by 5

Understanding Infection Risk with Anti-BCMA Bispecific Antibodies

Garfall, A. L., & Stadtmauer, E. A. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0157 · Cited by 5

The Real World Impact of Immunoglobulin Replacement Therapy on Severe Bacterial Infection for Patients With Hypogammaglobulinemia Secondary to Hematologic Malignancies: A Japanese Claims Database Study

Mihara, K., Kawase, T., Miyama, T., Iwasaki, K., Shoji, A., & Matsumaru, M. (2025) · eJHaem · doi:10.1002/jha2.70091 · Cited by 4

A case of hepatitis B virus reactivation after elranatamab therapy in a patient with multiple myeloma

Nishimura, N., Nakashima, H., Yoshikuni, K., Numata, A., & Ogawa, R. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00506-6 · Cited by 4

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies

Paulsen, J. S., & Slørdahl, T. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1722579 · Cited by 4

Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?

Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4

Towards personalized and rational use of immunoglobulins amid expanding indications and shortages

Goubran, H. A., Ragab, G., Seghatchian, J., & Burnouf, T. P. R. (2024) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2024.103987 · Cited by 4

Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management

Saltarella, I., Altamura, C., Solimando, A. G., D’Amore, S., Ria, R., Vacca, A., Desaphy, J., & Frassanito, M. A. (2024) · Cancers · doi:10.3390/cancers16183190 · Cited by 4

Treatment of elderly and frail myeloma patients.

Shih, S., Visram, A., & Mian, H. (2024) · Presse medicale · doi:10.1016/j.lpm.2024.104266 · Cited by 4

Practical insights into bispecific antibody therapy in multiple myeloma

Kawasaki, Y., Winger, S., Esteghamat, N., Rosenberg, A. S., & Beechinor, R. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2445145 · Cited by 4

Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions

Wonnaparhown, A. M., Hilal, T., Chong, A. C., & Fonseca, R. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101316 · Cited by 4

How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy

Davis, J. A., McGann, M., Marini, J., & Hashmi, H. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344650 · Cited by 4

Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention

Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 5

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Talarico, M., Barbato, S., Maisnar, V., Delimpasi, S., Puppi, M., Rizzello, I., Pantani, L., Tacchetti, P., Martello, M., Vigliotta, I., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06326-3 · Cited by 4

Infectious complications of chimeric antigen receptor T cell therapy and bispecific antibodies – A review

Dye, B., Gromer, D. J., Bibi, M., Siegrist, E. A., & Sassine, J. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.007 · Cited by 3

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Chakraborty, R., Bhutani, D., & Lentzsch, S. (2025) · Hematology. American Society of Hematology. Education Program · doi:10.1182/hematology.2025000760 · Cited by 3

Reshaping multiple myeloma treatment: recent breakthroughs

Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 4

Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit

Rodriguez, C., Touzeau, C., Crusoé, E. D. Q., Pericole, F. V., & Hungria, V. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.015 · Cited by 3

Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience

Marneni, N., Lessans, S., Dholaria, B., Sengsayadeth, S. M., Biltibo, E. A., Patel, V. G., Bhaskar, S., Jayani, R., Mohan, S. R., Kishtagari, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1721820 · Cited by 3

Bispecific T-cell engagers in autoimmune diseases: mechanisms of action, clinical evidence challenges, and therapeutic perspectives

Larue, M., Bitoun, S., Zuber, J., Michel, M., & Talbot, A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104060 · Cited by 5

How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies

Rejeski, K., Banerjee, R. K., & Hill, J. A. (2026) · Blood · doi:10.1182/blood.2025032298 · Cited by 3

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Howard, A. J., Concepcion, I., Wang, A. X., Hamadeh, I. S., Hultcrantz, M. L., Mailankody, S., Tan, C. R. C., Korde, N., Lesokhin, A. M., Hassoun, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012871 · Cited by 3

Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group

Moore, S. E., Miller, H., Parrish, C., Seymour, F., Miller, L. J., Chandler, T., Land, J., Karpha, I., Brearton, G., Thompson, S., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70041 · Cited by 4

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement

Lancman, G., Song, K., White, D., Crosbie, T., Sharif, I., Emond, M., Raza, M. S., Elias, M., Kaedbey, R., & Chu, M. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1446995 · Cited by 3

Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases

Guo, Z. K., Zhu, J., Wang, J., Wang, L., Tang, F., Huang, H., Xia, Z., Liu, L., Wang, D., Zhong, N., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1544025 · Cited by 2

CAR-T for multiple myeloma: practice pearls

O'Leary, D., & Bachanová, V. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02582-6 · Cited by 2

Bispecific T-cell engager therapy for multiple myeloma

Cirstea, D. D., Puliafito, B. R., Kim, B. E., Lei, M., & Raje, N. S. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101649 · Cited by 2

The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma

Zhou, X., Luo, E., Chen, W., Deng, Y., Wu, B., Jiang, X., Zhang, K., & Lai, F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1593405 · Cited by 2

Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies

Bilbao, I., Ansón, M., Villar, S., Pineda, I., Gárriz, L., Pina‐Sánchez, M., Tamariz‐Amador, L., Rodríguez‐Otero, P., Yuste, J. R., & del Pozo, J. L. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf672 · Cited by 2

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis

Tan, C. R., Usmani, S. Z., Derkach, A., Corraes, A. D. M. S., Parrondo, R. D., Ailawadhi, S., Asoori, S., Dave, M., Popat, R., Morjaria, O., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025019231 · Cited by 2

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Benda, M., Reimann, P., Willenbacher, W., Gunsilius, E., Weisel, K. C., Straßl, I., Krauth, M. T., Knop, S., Winder, T., & Steiner, N. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07140-8 · Cited by 2

T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement

van Voss, M. R. H., Molenaar, R. J., Korst, C. L. B. M., Bartelink, I. H., Baglio, S. R., Kruyswijk, S., de Ruijter, M. E. M., Zweegman, S., Kuipers, M. T., & van de Donk, N. W. C. J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2397436 · Cited by 2

Infections during novel myeloma therapies

Liu, A. J., Slavin, M. A., Harrison, S. J., & Teh, B. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2428819 · Cited by 2

Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study

Ghia, D., Thota, P., Ritchie, T., Rana, H., Minhas, R., Moolji, J., Ritchie, B. C., & Adatia, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316797 · Cited by 2

Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma

Giles, H. V., & Kishore, B. (2026) · Antibodies · doi:10.3390/antib15010005 · Cited by 2

Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies

Goede, J. S., Baumann, C. K., Cathomas, R. L., Khanna, N., Lambert, J., Lehmann, T., Mey, U., Seebach, J. D., Steiner, U. C., Tschan‐Plessl, A., et al. (2024) · Swiss Medical Weekly · doi:10.57187/s.3559 · Cited by 1

An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma

Bayly-McCredie, E., Prince, H. M., Yannakou, C. K., & Fiorenza, S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2479631 · Cited by 1

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Pelland, A.-A., Dumas, M., Lemieux‐Blanchard, É., LeBlanc, R., Côté, J. A., Boudreault, J., Duquette, D., Kaedbey, R., Lalancette, M., Larose, F., et al. (2025) · Current Oncology · doi:10.3390/curroncol32040238 · Cited by 1

Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma–Experience from Asian Countries

Soekojo, C. Y., Chung, S. J., Tsai, M.-T., Chen, W.-M., Huang, J., Kim, J. S., Lee, D., Min, C., Suzuki, K., Swaminathan, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.005 · Cited by 1

Reversing the sequence: Efficacy of BCMA‐directed therapy following progression on GPRC5D ‐directed therapies in relapsed multiple myeloma

Joiner, L., Giri, S., Ravi, G., Godby, K. N., Hagedorn, C., Costa, L. J., & Bal, S. (2025) · British Journal of Haematology · doi:10.1111/bjh.70176 · Cited by 1

Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma

Kitamura, A., Fujita, S., Isono, Y., Nakano, T., Morino, T., Tozuka, K., Kudo, H., Abe, R., Kohashi, S., & Toyama, T. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102851 · Cited by 1

Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma

Suzuki, T., & Iida, S. (2025) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.25038 · Cited by 2

Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions

Piron, B., Moreau, P., & Touzeau, C. (2026) · Biologics · doi:10.2147/btt.s539066 · Cited by 3

Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies

Cao, W., meng, F., Feng, S., Zhao, M., Song, J., Sun, Y., Cao, W., Tian, W., Hu, Y., Fan, F., et al. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70107 · Cited by 1

Significant burden of low-grade infections in patients treated with T-cell−engaging therapies for multiple myeloma

Mersi, J., Burow, L., Zhou, X., Eisele, F., Fante, M., Riedhammer, C., Stich, A., Isberner, N., Afrin, N., Duell, J., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017889

Infektionen unter Therapie mit bispezifischen Antikörpern bei malignen Lymphomen, dem multiplen Myelom und der akuten lymphatischen Leukämie

Ruckdeschel, A. M., von Herder, J., Giesen, N., Sandherr, M., Rieger, C., & Teschner, D. (2026) · best practice onkologie · doi:10.1007/s11654-026-00714-y · Cited by 1

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Lancman, G., Parsa, K., Rodriguez, C., Richter, J. R., Cho, H. J., Parekh, S. S., Richard, S., Rossi, A., Sanchez, L. J., Thibaud, S., et al. (2022) · Blood · doi:10.1182/blood-2022-163733 · Cited by 48

Immunoglobulin May Prevent Infections in Patients With Multiple Myeloma

(2023) · Oncology Times · doi:10.1097/01.cot.0000996488.11406.21

Prophylactic intravenous immunoglobulin in patients receiving BCMA-targeted bispecific antibody therapy for multiple myeloma: A systematic review and meta-analysis

Bezerra, G. N., Passos, P. R. C., Noronha, M. M., Luciano, P. H. C., Filho, V. O. C., Ferri, G. M., & Filho, C. M. D. O. (2025) · Blood · doi:10.1182/blood-2025-5754 · Cited by 2

Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

Cani, L., Scott, S. A., Roberts, D., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Lonial, S., Nooka, A. K., & Kaufman, J. L. (2025) · Haematologica · doi:10.3324/haematol.2025.288187 · Cited by 8

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis

Mazahreh, F., Mazahreh, L., Schinke, C., Thanendrarajan, S., Zangari, M., Shaughnessy, J. D., Zhan, F., van Rhee, F., & Al Hadidi, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009435 · Cited by 142